{"id":"exc-001","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Unfortunately, I do not have enough information to provide a deeper explanation of the mechanism.","oneSentence":"EXC 001 is a small molecule that targets the [insert target here, if known].","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T02:33:04.710Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Phase 2 for [insert indication here, if known]"}]},"trialDetails":[{"nctId":"NCT01038297","phase":"PHASE2","title":"Safety and Efficacy Study of Different Dose Levels of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-12-01","conditions":"Scar Prevention","enrollment":30},{"nctId":"NCT01346969","phase":"PHASE2","title":"Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-06-01","conditions":"Reduction in Hypertrophic Skin Scarring","enrollment":68},{"nctId":"NCT01494922","phase":"PHASE2","title":"Safety and Efficacy of EXC 001 in Subjects Who Have Participated in Prior Studies of EXC 001","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-12-08","conditions":"Reduction in Severity of Skin Scarring","enrollment":14},{"nctId":"NCT01037985","phase":"PHASE2","title":"Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-12-03","conditions":"Scar Prevention","enrollment":41},{"nctId":"NCT01037413","phase":"PHASE2","title":"Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-12-22","conditions":"Scar Prevention","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"EXC 001","genericName":"EXC 001","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"EXC 001 is a small molecule that targets the [insert target here, if known]. Used for Phase 2 for [insert indication here, if known].","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":4,"withResults":4},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}